CLSA Events

CEO and CFO Roundtables World of Incentives: Stock Options: Benefit or Burden? | Part One

CEO and CFO Roundtables | World of Incentives

This two-part Executive Series Roundtable will discuss compensation package design issues: industry veterans will share their experience with both equity and non-equity components, they try to answer the single most important question: how do you design an incentive program that helps retain top talent?

Stock Options: Benefit or Burden? | Part One

There is an on-going debate if stock options remain a viable tool to motivate life science company staff and management. With the M&A activity as a primary exit route for most private companies the prospect of cashing company stock is nonexistent. So, how are your stock option programs changing and what should your plan look like? With the financial pressures mounting, how do you balance between the wants of your employees and the needs of your investors?

The questions are different for the public companies: short term vs. long term; what is sustainable? Is the Board Compensation Committee review a new reality?

Moderator

Laura Berezin
Partner, Hogan Lovells US LLP

Anchors

Rick Orr
CEO, Adynxx, Inc.

Diana M. Petty, SPHR
VP Human Resources & Administration, Metabolex, Inc.

William Waddill
Senior Vice President and CFO, OncoMed Pharmaceuticals Inc.

Matt Ward
National Practice Leader, Compensation, Barney & Barney LLC

What: CEO and CFO Roundtables
World of Incentives: Stock Options: Benefit or Burden? | Part One
When: September 20, 2011
5:30pm– 7:30pm
Where: OncoMed Pharmaceuticals, Inc.
800 Chesapeake Dr.
Redwood City, CA 94063-4748
Directions
Parking: Complimentary On-Site
Attire: Business attire suggested
Attendance: RSVP by September 16th is required
No on-site registrations accepted

Open to C-Suite Executives of Life Sciences Companies Only.
Cost: BayBio Members – FREE
Non-Members – $75.00